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SUPPLEMENTARY METHODS
Determination of equilibrium dissociation constants (K D ) for thiol/Michael acceptor adducts
Reactions of cyanoacrylates and cyanoacrylamides with BME, GSH, ethanolamine, and lysine were monitored with a Spectramax M5 plate reader (Molecular Devices, Sunnyvale CA).
Reactions were initiated by mixing equal volumes of the Michael acceptor (200-400 M in PBS, pH 7.4) with the thiol (0-200 mM BME or GSH in PBS pH 7.4, two-fold dilution series). Final solutions (Costar flat-bottom clear 96-well plate, 100 L per well), containing 100-200 M Michael acceptor and increasing concentrations of BME/GSH, were incubated for 10 min at room temp prior to acquiring absorption spectra (250-500 nm). Equilibration of these doubly activated Michael acceptors with BME or GSH occurred within seconds or less (as determined by sequential absorbance measurements, data not shown). Formation of the thiol adduct was quantified by monitoring the disappearance of the absorbance peak ( max ) relative to the no-thiol control sample. Data were fit using PRISM 4.0 to obtain equilibrium dissociation constants.
Test reactions of CN-NHiPr with ethanolamine or lysine were also carried out. Reactions were initiated as described above by mixing equal volumes of CN-NHiPr (100 µM in PBS, pH 7.4) with solutions of ethanolamine or lysine (0.1-100 mM amine solution in PBS pH 7.4). In a second experiment, a solution of cyanoacrylate 3 (5.1 mg, 27.3 mol) in 0.75 mL of DMSO-d6 was added to 0.25 mL of 400 mM BME in deuterated PBS. Analysis of the reaction mixture by 1 H NMR indicated a >95:5 ratio of the thiol adduct 6 to the starting cyanoacrylate 3.
The sample was then allowed to stand at ambient temperature. The ratio of adduct 6 to starting cyanoacrylate 3 changed with time as the excess BME in solution underwent air oxidation to the corresponding disulfide. After 17 days, the ratio of 6:3 was <5:95 (data not shown).
Characterization of the BME adduct 6.
For the purpose of characterization, a solution of cyanoacrylate 3 (13.5 mg) in DMSO-d6
(0.75 mL) was treated with 1.2 M BME in deuterated PBS (0.25 mL) to drive the reaction towards the adduct 6 (final concentrations of cyanoacrylate 3 and BME were 72 mM and 300 mM respectively). Dried blots were exposed for 30 min to a storage phosphor screen and scanned by a Typhoon imager (GE Life Sciences). The data were quantified using ImageQuant 5.2 software and fit using PRISM 4.0. The lysates were cleared by centrifugation at 14K rpm for 10 min at 4˚C, and normalized by Bradford assay. Laemmli sample buffer was added to the lysates and the proteins were separated by 7.5% SDS-PAGE and analyzed by immunoblot using phospho-Ser386 RSK (1:500 dilution, rabbit Ab, Cell Signaling #9341) and RSK2 (E-1) (1:500 dilution, mouse monoclonal, Santa
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Cruz cs-9986) antibodies. Immunoblots were developed and imaged as described 
RSK2-CTD expression and purification
RSK2-CTD (mouse RSK2 399-740) was expressed in E. coli strain BL21 (DE3)-RIL (pET-46
Ek/LIC His6-fusion vector was kindly provided by M. Malakhova and Zigang Dong, University of Minnesota). Cells were lysed in lysis buffer (50 mM Tris pH 8.0, 0.5 M NaCl, 10% glycerol, 15 mM imidazole) using a homogenizer (EmulsiFlex-C5, Avestin) operated at 15000 psi at 4˚C
for 15 min (continuous flow lysis). Soluble His-tagged RSK2-CTD was purified by Ni/NTA affinity chromatography (50 mM Tris pH 8.0, 0.5 M NaCl, 10 mM imidazole) using a 10 mL column at 2 mL/min flow rate with gradient elution (10-500 mM imidazole), followed by cleavage of the His 6 -tag with enterokinase (1U per 1 mg protein) (EMD Biosciences) at 4˚C.
The cleaved RSK2-CTD was further purified by HiLoad 16/60 Superdex-75 size exclusion 23 chromatography (20 mM Tris pH 8.0, 50 mM NaCl, 1 mM DTT) and the protein eluted as a single peak at 55 mL, corresponding to a monomer. Purified protein was concentrated and flash frozen in liquid nitrogen in 20 mM Tris pH 8.0, 50 mM NaCl, 1 mM DTT, 12% glycerol and stored at -80˚C. Protein concentrations were determined using the calculated extinction coefficients at 280 nm measured with a NanoDrop1000 spectrophotometer (Thermo Scientific).
RSK2-CTD crystallization and data collection
Initial RSK2-CTD crystallization conditions were determined through conventional screens. Purified RSK2-CTD was concentrated to 5-10 mg/mL in 20 mM Tris pH 8.0, 50 mM NaCl, 1 mM DTT, and then incubated with one molar equivalent of tert-butyl cyanoacrylate 16. problems: significant overlapping or spots, and highly anisotropic data sets. Overlap was minimized as described above and by reorienting the crystal in the beamline. We were unable to improve on the anisotropy of the crystal, which subsequently resulted in higher than expected Bfactors.
Drops of 1 l
Structure determination
Prior to solving the liganded RSK2-CTD structure, we first re-solved the structure of apo-RSK2-CTD. We expressed the protein as described above, recrystallized it, and collected data sets on ALS Beamline 8.3.1, with the exception that we flash froze the crystals in Paratone oil (Hampton Research). These crystals exhibited significantly higher resolution (~1.9 Å), with less mosaicity. After processing the data sets using XDS, we solved the structure by molecular replacement using 2qr8 as a search model 5 . Interestingly, our data sets enabled us to build residues N-terminal to the reported structure out to residue 406 (data not shown). We then used this structure as a model for molecular replacement in solving the liganded crystal structures.
The liganded complexes were modeled by several rounds of manual rebuilding and restrained refinement with programs Coot 6 and Phenix.refine . Ligands were then built in ChemDraw (CambridgeSoft), and exported in SMILES string format and read into PhenixELBOW to generate both a coordinate and restraint file that were used during model building and refinement. Before adding the ligand to the model, it was clear from the electron density map where the ligand would be placed in the pocket, and that it was covalently linked to Cys436. After ligand placement in this density, the ligand was redrawn with a tetrahedral carbon at the C11 attachment position. The previous ligand was then replaced with the newer one, and the structure refined with Phenix. and phosphatase (PhoStop, Roche) inhibitors. The lysates were cleared by centrifugation at 14K rpm for 10 min at 4˚C and normalized by Bradford assay. Laemmli sample buffer was added to 27 the lysates and the proteins were separated by 10% SDS-PAGE and detected by in-gel fluorescence scanning (Typhoon 9400), followed by Coomassie blue staining.
Kinase profiling
Supplementary Table 1 
Synthetic chemistry methods
Except as otherwise indicated, reactions were carried out under dry argon or nitrogen with dry solvents. Dry solvents were dispensed from a delivery system that passes the solvents through packed columns (tetrahydrofuran, acetonitrile, and methylene chloride: dry neutral alumina; dimethylformamide: activated molecular sieves). All other reagents were purchased from commercial sources and used as received.
Yields of reactions refer to chromatographically and spectroscopically pure compounds.
Reactions were monitored by thin layer chromatography (TLC) using glass plates precoated with Electron Corporation LTQFT spectrometer using electrospray ionization with FT resolution set to 30000, and reported mass values are within the error limits of ± 5 ppm mass units.
Methyl 2-cyano-3-phenylacrylate 3
To a solution of benzaldehyde (1.28 g, 12.06 mmol) and methyl cyanoacetate (1.21 g, 12.21 mmol, 1.01 equiv) in 2-propanol (5 mL) was added piperidine (150 L, 1.52 mmol, 0.13 equiv). The reaction mixture was heated to 60˚C for 2 h and DI water (15 mL) was added dropwise. The resulting slurry was cooled to 0-5˚C for 15 min and filtered. The filter cake was washed with 2-propanol:DI water (1:3 v/v, 30 mL) and dried in vacuo to afford a white solid (ca. 
Methyl 3-(2-hydroxyethylthio)-3-phenylpropanoate 4
To a solution of trans-methylcinnamate 1 (133.5 mg, 0.823 mmol) and triethylamine (115 L, 1.0 equiv) in MeOH (3 mL) was added BME (173 L, 3.0 equiv). The reaction mixture was maintained at 20-25˚C and after 2.5 h additional BME (200 L, 3.5 equiv) was added. The reaction mixture was maintained at 20-25 ºC for an additional 45.5 h, at which point complete conversion of the cinnamate was observed. The reaction mixture was concentrated and the residue was purified by silica gel chromatography (3: 
3-(2-hydroxyethylthio)-3-phenylpropanenitrile 5
To a solution of cinnamonitrile 2 (204.6 mg, 1.58 mmol) in DMF (2 mL) was added 3 mL of a solution of 2-mercaptoethanol (BME, 5M) in phosphate buffered saline (PBS). The reaction mixture was maintained at 20-25˚C for 11 days at which point complete conversion was observed. The reaction mixture was diluted with EtOAc (50 mL) and washed with DI water (4 x 31 25 mL). The combined aqueous washes were extracted with EtOAc (50 mL 
.
General procedure for the preparation of 2-cyanoacrylamides 7-11
In a 2 mL vial fitted with a magnetic stir bar was combined the aldehyde (0.1 mmol, purchased from Aldrich), 2-cyanoacetamide (16 mg, 0.2 mmol), piperidine (0.01 mL, 0.1 mmol), and 2-propanol (0.3 mL). The mixture was stirred at room temp or 60˚C for 1-18 h. Products that precipitated from the reaction mixture were isolated by filtration, washed with water, and dried in vacuo. Products that did not precipitate were extracted with EtOAc and water. The organic layer was then dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure.
The resulting residue was then purified by silica gel chromatography (elution with EtOAc). 
3-(4-(1H-Imidazol-1-yl)phenyl)-2-cyanoacrylamide (7). Yield: 23 mg (97%
2-Cyano-3-(6-(4-(methylsulfonyl)phenyl)pyridin-2-yl)acrylamide (9). Yield: 12 mg (37%
2-Cyano-3-(thiophen-3-yl)acrylamide (10).
In a 20 mL vial fitted with a magnetic stir bar was dissolved 2-cyanoacetamide (80 mg, 1 mmol) in 10% NaHCO 3 (3 mL). To the solution was added 3-thiophene carboxaldehyde (101 mg, 0.9 mmol) and the resulting mixture was stirred vigorously for 3 h at room temp. The product was isolated by filtration, washed with water and dried in vacuo. Yield: 123 mg (69% 
2-Cyano-3-(1H-imidazol-5-yl)acrylamide (11).
In a 20 mL vial fitted with a magnetic stir bar was dissolved 2-cyanoacetamide (80 mg, 1 mmol) in 10% NaHCO 3 (3 mL). To the solution was added 4 (5) 
(E)-methyl 3-(4-amino-7-(3-hydroxypropyl)-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)acrylate 12
Bromide A was synthesized as previously reported 
(E)-3-(4-amino-7-(3-hydroxypropyl)-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)acrylonitrile 13
A flame dried 50 mL round bottom flask was charged with aldehyde B (218 mg, 0.41 mmol; prepared under contract by Albany Molecular Research Inc., Albany, NY; details available upon request) and (triphenylphosphoranylidine)acetonitrile (500 mg, 4 equiv). CH 2 Cl 2 (10 mL) was added and the reaction mixture was stirred at room temp. After 16 h the reaction was complete and the crude mixture after concentration was adsorbed on silica and purified by column chromatography (20% EtOAc/hexanes isocratic) to yield the protected nitrile, which was dissolved in CH 2 Cl 2 (2 mL) and was cooled to 0˚C. TFA (2 mL) was added dropwise and the reaction mixture was allowed to warm to room temp. After 12 h the reaction mixture was concentrated and the residue redissolved in THF (3 mL). The solution was cooled to 0˚C and 1N HCl (1 mL) was added after which the reaction mixture was allowed to warm to room temp.
After 4.5 h the deprotection was complete and the reaction mixture was diluted with 10 mL of EtOAc. The organic phase was washed with saturated aqueous sodium bicarbonate (2 x 15 mL), brine (2 x 15 mL), dried over MgSO 4 and concentrated. The residue was adsorbed on silica and purified by column chromatography (3% MeOH in EtOAc, isocratic) to yield 9.1 mg (11.4%) of acrylonitrile 13. 
General procedure for the preparation of cyanoacrylates and cyanoacrylamides 14 -16
To a solution of aldehyde C (0.3 mmol) in THF (2 ml) were added DBU (1.2 equiv) and the appropriate cyanoacrylate or cyanoacetamide (1.2 equiv). The reaction was stirred at room temp until all the starting material had been consumed. The reaction mixture was concentrated and the residue was purified by flash column chromatography to give the TBS-protected products.
38
To a solution of the TBS-protected cyanoacrylates or cyanoacrylamides (0.1 mmol) in THF (1 ml) was added 1N aqueous HCl. The reaction mixture was stirred at room temp for 1.5 h and then diluted with ethyl acetate. The organic layer was washed with saturated aqueous sodium bicarbonate followed by brine and then dried over sodium sulfate, filtered and concentrated. The residues were purified by flash column chromatography in 100% EtOAc  5% MeOH/EtOAc to give the desired compounds 14-16.
Methyl 3-(4-amino-7-(3-hydroxypropyl)-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-2-cyanoacrylate 14
Cyanoacrylate 14 was prepared in 22% yield from methyl 2-cyanoacetate and aldehyde 
C.
3-(4-amino-7-(3-hydroxypropyl)-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-2-cyano-Nisopropylacrylamide 15 (CN-NHiPr)
Cyanoacrylamide 16 was prepared in 13% yield from N-isopropylcyanoacetamide 11 and aldehyde C. 
(FMK-BODIPY)
To 
(CN-NHiPr-BODIPY)
To a solution of carbamate H (5.2 mg, 6.6 µmol, 1.5 equiv) in CH 2 Cl 2 (0.5 mL) was added TFA (0.5 mL) at 20-25˚C. The reaction mixture was maintained at ambient temperature for 3 h, then concentrated under reduced pressure to afford a yellow oil. A solution of BODIPY-TMR-X, SE (2.5 mg, 4.1 mol, 1.0 equiv) in DMF (1 mL) was then added to the oil followed by DIPEA (7.2 L, 10.0 equiv). The reaction mixture was maintained at ambient temperature for 24 h while protected from light, then concentrated under reduced pressure to afford a purple oil. 
Alcohol K
To a solution of DiBoc pyrrolopyrimidine H (113.1 mg, 0.190 mmol) in THF (3 mL) was added 1M aqueous HCl (1 mL). The reaction mixture was maintained at 20-25˚C for 1 h, then quenched with saturated aqueous NaHCO 3 (5 mL) and extracted with EtOAc (3 x 5 mL). The combined organic extracts were dried (MgSO 4 ) and concentrated to afford a colorless oil, which was purified by preparative TLC (1:2 Hexanes:EtOAc) to afford the alcohol K as a colorless oil, 
mg (84% yield
(scaffold-BODIPY)
To a solution of carbamate L (10.8 mg, 14.3 mol, 3.5 equiv) in CH 2 Cl 2 (1 mL) was added TFA (1 mL) at 20-25˚C. The reaction mixture was maintained at ambient temperature for 3 h, then concentrated under reduced pressure to afford a colorless oil. A solution of BODIPY-TMR-X, SE (2.5 mg, 4.1 mol, 1.0 equiv) in DMF (1 mL) was then added to the oil followed by DIPEA (7.2 L, 10.0 equiv). The reaction mixture was maintained at ambient temperature for 24 h while protected from light, then concentrated under reduced pressure to afford a purple oil. 
